Aviceda’s executive team will join Truist Securities Biotech Analyst Joon Lee, MD, PhD, for a Virtual Fireside Chat hosted by Truist. Register here for the event on October 15 at 2:00pm ET: https://lnkd.in/e-b8tR76 #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #clincialtrials
Aviceda Therapeutics’ Post
More Relevant Posts
-
In SeqBiome, we pride ourselves on the quality of service we provide our customers. We are delighted and proud to have this formalised in our recent certification to the #ISO9001 standard, ensuring continued quality and #continuousimprovement in everything we do. A huge thanks to the entire team lead by Ciara O' Donovan for their hard work in achieving this important milestone. www.seqbiome.com #qualityservice #operationalexcellence #qualitymicrobiomeanalysis #microbiota #microbiomeresearch #microbiomesequencing #bioinformatics #clinicalresearch #Metagenomics #Metabolomics #clinicaltrials
To view or add a comment, sign in
-
FSD Pharma has a remylenating drug called Lucid MS that can target all forms of MS. The idea exists that MS has a neurodegenerative component seperate from the auto immune aspect. Thus the need for remyelinating therapies for multiple sclerosis patients around the world. Any stakeholders that want more info reach out to me , including #investmentbanking community thanks.
Recap Video On Our Drug Candidate Lucid-MS targeting all forms of Multiple Sclerosis #Multiplesclerosis #Biotechnology #Nasdaq
To view or add a comment, sign in
-
❓ Have you already planned your trip to Dresden? ➡️ If not, then take a look at the website, where we have compiled all the important information for you: https://lnkd.in/eq59ddaQ #HUPO2024 #Proteomics #humanproteomics #clinicalproteomics #Microbiome #cellbiology #Bioinformatics
To view or add a comment, sign in
-
Biogen, UCB report phase 3 lupus win, justifying risky bet on asset that failed earlier trial. Biogen and UCB plan to move patients in the existing trial into a long-term open-label study and start a second phase 3. Biogen and UCB’s gamble on advancing into phase 3 on the back of a failed study looks to have paid off, with the partners reporting positive top-line results in systemic lupus erythematosus (SLE) and outlining plans to start a second pivotal trial... Check out the full story 👉 https://zurl.co/2r7J (Fierce Biotech) #biotech #genetics
To view or add a comment, sign in
-
Enlivex (Nasdaq: $ENLV), a leader in macrophage reprogramming immunotherapy, has launched a brand new website! Discover their innovative Allocetra™ therapy, designed to reset macrophages and rebalance the immune system. Visit now to learn more: https://ow.ly/pey450SSmEK #macrophages #immunesystem #osteoarthritis #Biotechnology #biotech #stocks #stockmarket #nasdaq #StockMarketNews
To view or add a comment, sign in
-
This month's meeting of the #SGO kicks off this Saturday!! Here we present the titles of the key abstracts that will be presented at the #conference. For further details, conference coverage support, pipeline analysis and other CI services, contact rishi.srivastava@datazymes.com #Immunotherapy, #CancerResearch, #Immunooncology, #CancerTreatment, #Biotechnology, #ImmuneCheckpointInhibitors, #ClinicalTrials, #Biomarkers, #CancerImmunology, #Immunomodulation, #TumorMicroenvironment, #TargetedTherapeutics, #ImmunotherapeuticApproaches, #ImmuneResponse, and #OncologyAdvancements
To view or add a comment, sign in
-
Enlivex (Nasdaq: $ENLV), a leader in macrophage reprogramming immunotherapy, has launched a brand new website! Discover their innovative Allocetra™ therapy, designed to reset macrophages and rebalance the immune system. Visit now to learn more: https://ow.ly/s1hT50SSmEL #macrophages #immunesystem #osteoarthritis #Biotechnology #biotech #stocks #stockmarket #nasdaq #StockMarketNews
To view or add a comment, sign in
-
At this year's Macula Society meeting, join #retina specialist Peter Kaiser, MD, as he discusses findings from the Part 1 of the Phase 2/3 SIGLEC study assessing the safety and efficacy of AVD-104 for the treatment of GA. #glycoimmunology #knowga #biotech #innovation #ophthalmology
To view or add a comment, sign in
-
Genomics Market worth $83.1 billion by 2028 Download PDF Brochure:-https://lnkd.in/duhBQxjx The global genomics market in terms of revenue was estimated to be worth $46.2 billion in 2023 and is poised to reach $83.1 billion by 2028, growing at a CAGR of 12.4% from 2023 to 2028. The prominent genomics product and service providers are Illumina, Inc. (US), Thermo Fisher Scientific, (US), Danaher Corporation (US), QIAGEN (Germany), Agilent Technologies, (US), and PerkinElmer Inc. (US). #genomics #ngs #genome #biotechnology
To view or add a comment, sign in
-
Attending WRIB? Schedule a meeting with our scientific experts to learn how we can partner on your drug development journey. Sign up here to have an expert reach out to you to set up a meeting: https://bit.ly/3TSxdyc #WRIB #bioanalysis #spatialbiology #spatialomics #oligo
To view or add a comment, sign in
3,560 followers
Co-Founder, CEO & President @ Aviceda Therapeutics | Serial Entrepreneur | Retina Specialist
1moThank you Joon Lee for an insightful fireside chat, always a pleasure!